These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30565417)

  • 41. [Cure effect and persistence of treatment with Mirabegron in patients with symptoms of overactive bladder: a multicentre clinical study].
    Martan A; Mašata J; Švabík K; Hanuš T; Krhut J; Zachoval R
    Ceska Gynekol; 2017; 82(6):424-429. PubMed ID: 29302974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
    Rovner ES; Carlson KV; Deal AS; Nair KV; Oakkar EE; Park J; Gemmen E; Kristy RM; Gooch KL; Schermer CR
    Contemp Clin Trials; 2018 Jul; 70():83-87. PubMed ID: 29777865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder.
    Wang CC; Lee CL; Hwang YT; Kuo HC
    Low Urin Tract Symptoms; 2021 Oct; 13(4):440-447. PubMed ID: 33960119
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).
    Otsuka A; Kageyama S; Suzuki T; Matsumoto R; Nagae H; Kitagawa M; Furuse H; Ozono S
    Int J Urol; 2016 Dec; 23(12):1016-1023. PubMed ID: 27686226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [MIRABEGRON. WHETHER WILL BE A REVOLUTION IN THE PHARMACOTHERAPY OF OVERACTIVE BLADDER?].
    Romikh VV; Borisenko LY; Zakharchenko AV
    Urologiia; 2015; (5):110-2, 114-7. PubMed ID: 26859952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort.
    Peyronnet B; Vurture G; Palma JA; Malacarne DR; Feigin A; Sussman RD; Biagioni MC; Palmerola R; Gilbert R; Rosenblum N; Frucht S; Kaufmann H; Nitti VW; Brucker BM
    Parkinsonism Relat Disord; 2018 Dec; 57():22-26. PubMed ID: 30037689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.
    Matsukawa Y; Takai S; Funahashi Y; Yamamoto T; Gotoh M
    Urology; 2015 Apr; 85(4):786-90. PubMed ID: 25709050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
    Kim SC; Park M; Chae C; Yoon JH; Kwon T; Park S; Moon KH; Cheon SH; Park S
    Investig Clin Urol; 2021 May; 62(3):317-323. PubMed ID: 33834641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Persistence in the treatment of overactive bladder (OAB) with Mirabegron in a multicentre clinical study].
    Martan A; Mašata J; Švabík K; Hanuš T; Krhut J
    Ceska Gynekol; 2015 Aug; 80(4):244-8. PubMed ID: 26265411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.
    Kallner HK; Christensson AA; Elmér C; Flam B; Altman D
    Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():167-72. PubMed ID: 27318184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.
    Castro-Diaz D; Chapple CR; Hakimi Z; Blauwet MB; Delgado-Herrera L; Lau W; Mujais S
    Qual Life Res; 2015 Jul; 24(7):1719-27. PubMed ID: 25688038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR; Siddiqui E
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study.
    Kakizaki H; Lee KS; Katou D; Yamamoto O; Sumarsono B; Uno S; Yamaguchi O
    Adv Ther; 2021 Jan; 38(1):739-757. PubMed ID: 33245533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.
    Kinjo M; Masuda K; Nakamura Y; Miyakawa J; Tambo M; Fukuhara H
    Urology; 2023 May; 175():67-73. PubMed ID: 36822245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
    Angulo JC; Khullar V; Nitti VW; Siddiqui E
    Actas Urol Esp; 2013; 37(10):640-51. PubMed ID: 23850394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.